Know Cancer

or
forgot password

Phase 1/2a, Multicenter, Open-Label Study Designed to Evaluate the Safety, Tolerability and Preliminary Efficacy of ApoCell Administration, a Donor Apoptotic Cell-Based Product, for the Prevention of Acute Graft Versus Host Disease (GvHD) in Subjects With Hematologic Malignancies Undergoing Allogeneic Sibling HLA-Matched Hematopoietic Stem Cell Transplantation (HSCT)


Phase 1/Phase 2
18 Years
60 Years
Open (Enrolling)
Both
Graft Versus Host Disease, Hematological Malignancies

Thank you

Trial Information

Phase 1/2a, Multicenter, Open-Label Study Designed to Evaluate the Safety, Tolerability and Preliminary Efficacy of ApoCell Administration, a Donor Apoptotic Cell-Based Product, for the Prevention of Acute Graft Versus Host Disease (GvHD) in Subjects With Hematologic Malignancies Undergoing Allogeneic Sibling HLA-Matched Hematopoietic Stem Cell Transplantation (HSCT)


Allogeneic hematopoietic stem-cell transplantation (HSCT) has revolutionized the treatment
of hematopoietic malignancies, inherited hematopoietic disorders, aplastic anemia, and other
severe diseases. Unfortunately, graft versus host disease (GvHD) remains a major toxicity
that greatly limits the application and efficacy of allogeneic HSCT, occurring commonly
after the procedure and affecting 30 to 80% of patients. Acute GvHD occurs within 100 days
in up to 50% of allogeneic HLA-matched HSCT recipients despite prophylactic
immunosuppressive drugs.

The most efficient treatment for GvHD prevention is T cell depletion. However, most
clinicians avoid that modality due to the crucial effect of T cells in prevention of tumor
relapse. Current standard prophylaxis and therapy for acute GvHD include mainly the use of
immunosuppressive drugs that help less than 50% of the patients and are associated with
increased infection risk. New strategies of GvHD prophylaxis are examined and this study
uses a physiological strategy of antigen presenting cell (APC) tolerance induction that will
modulate effector cells either directly or via T regulatory cells.

ApoCell treatment is anticipated to be a prophylactic measure for acute GvHD by inducing
tolerance in the donor effector cells, leading to a potentially significant decrease in the
immune response of the donor cells against the recipient. The effects of apoptotic cells on
preventing GvHD may involve the following mechanisms: inhibit pro-inflammatory cytokine
production, promote anti-inflammatory cytokines production, induce tolarogenic APCs,
decrease ability to stimulate T-cell responses, delete CD8 T-effector cells, induce
regulatory T-cells, and inhibit response to inflammatory cytokines and LPS.

Tolarex Ltd. is proposing a novel cell-based approach of donor apoptotic cells treatment,
ApoCell, for a Phase I-IIa study of patients undergoing sibling HSCT with high risk of
developing acute GvHD. The ApoCell product is composed of HLA-matched donor mononuclear
enriched leukocytes in the form of liquid suspension that will be injected intravenously to
the patient 24 hours prior to HSCT. The ApoCell suspension contains at least 55% of early
apoptotic cells. The cell suspension is prepared under cGMP conditions with PBS solution
within 8 hours prior to intravenous injection and should be stored at 2-8oC until
administered.


Inclusion Criteria:

Recipient

1. Adult male or female subjects, 18-60 years of age, inclusive, at the time of
screening visit weighing at least 40 kg.

2. Subjects are eligible for allogeneic sibling HLA-matched HSCT for any disease for
which transplantation is appropriate except progressive or poorly controlled
malignancies. Only one of the following malignancies should be present:

1. Acute lymphoblastic leukemia or acute myeloid or undifferentiated or
biphenotypic, leukemia, in complete remission or beyond but with ≤10% blasts in
bone marrow.

2. Acute myeloid leukemia in complete remission if it has evolved from
myelodysplastic syndrome (MDS) (there should be documented diagnosis of MDS at
least 3 months prior to diagnosis of acute myeloid leukemia).

3. Myelodysplastic syndromes - MDS

4. Therapy related MDS (irrespective of IPSS).

5. Chronic myeloid leukemia (CML) chronic phase-1 (imatinib failures, imatinib
intolerance), or any CML beyond first chronic phase.

6. Multiple Myeloma.

3. The donor and recipient must have at least a 7/8 HLA match at the HLA A, B, C, and DR
loci.

4. Life expectancy of at least 6 months at the time of the baseline visit.

5. Karnofsky performance status score ≥ 80% at time of the screening visit.

6. Cardiac left ventricular ejection fraction ≥ 40% in adults within 4 weeks of
initiation of conditioning; required if prior anthracycline exposure or history of
cardiac disease.

7. Pulmonary function test with DLCO, FEV1 and FVC of ≥ 60%.

8. Oxygen saturation ≥ 90% on room air.

9. Subjects must have normal organ function as defined below:

1. AST (SGOT)/ALT (SGPT) ≤ 2.5 x upper limit of normal (ULN).

2. Serum creatinine <2.5 mg/dL.

3. Serum bilirubin <3 mg/dL.

4. Coagulation markers - PT and PTT within normal limits.

10. Signed written informed consent to participate in the study independently by subject.
Subjects requiring a guardian to sign informed consent will not be included.

11. Ability to comply with the requirements of the study.

12. If female, agree to use an acceptable method of birth control or be surgically
sterile, and have a negative pregnancy test regardless of child-bearing potential.

Exclusion Criteria: recipient

1. Participation in an investigational trial within 30 days of the screening visit.

2. Have progressive or poorly controlled malignancies.

3. T-cell depleted allograft.

4. Uncontrolled infections including sepsis, pneumonia with hypoxemia, persistent
bacteremia, or meningitis within two weeks of the screening visit.

5. Current known acute or chronic infection with HBV or HCV.

6. Known human immunodeficiency virus (HIV) infection or AIDS.

7. Subjects with severe or symptomatic restrictive or obstructive lung disease or
respiratory failure requiring ventilator support.

8. Subjects with other concurrent severe and/or uncontrolled medical condition which
could compromise participation in the study (i.e. active infection, uncontrolled
diabetes, uncontrolled hypertension, congestive cardiac failure, unstable angina,
ventricular arrhythmias, active ischemic heart disease, myocardial infarction within
six months, chronic liver or renal disease, active upper gastrointestinal tract
ulceration).

9. Any chronic or acute condition susceptible of interfering with the evaluation of
investigational product effect.

10. Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder
or any chronic condition susceptible, in the opinion of the investigator, of
interfering with the conduct of the study.

11. Organ allograft or previous history of allogeneic stem cell transplantation.

12. For all women: A positive pregnancy test at screening or breast-feeding.

13. Subjects who are likely to be non-compliant or uncooperative during the study.

Inclusion criteria: Donor

1. Male or female donors, 18 - 65 years of age, inclusive.

2. The donor and recipient must have at least a 7/8 HLA match at the HLA A, B, C, and DR
loci.

3. Above 40 kg.

4. Not pregnant and negative pregnancy test.

5. Serum creatinine < 2.5 mg/dL.

6. Oxygen saturation ≥ 90% on room air.

7. No severe or symptomatic restrictive or obstructive lung disease or respiratory
failure requiring ventilator support.

8. No uncontrolled hypertension or congestive heart failure, active angina pectoris
requiring the use of nitrates, or major ventricular arrhythmia or cardiac failure
requiring active treatment.

9. Not HIV-1/2 or HTLV I/II seropositive or evidence of acute CMV infection.

10. Not seropositive for Hepatitis B or C.

11. Not positive for syphilis.

12. No known bone marrow disease.

13. No significant organ dysfunction.

14. No acute infectious disease within two weeks of donation.

15. Willingness to donate hematopoietic blood mononuclear cells for the generation of
ApoCell more than one time if required and in addition to the donation for the HSCT.

16. Ability to provide written informed consent and comply with study requirements.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

Determine the safety profile and tolerability [dose limiting toxicity (DLT)] of ascending doses of ApoCell in subjects undergoing allogeneic sibling HLA-matched HSCT within 180 days post-transplantation.

Outcome Time Frame:

180 days

Safety Issue:

Yes

Principal Investigator

Reuven Or, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hadassah Medical Organization

Authority:

Israel: Ethics Commission

Study ID:

TLX-APO-101IL-HMO-CTIL

NCT ID:

NCT00524784

Start Date:

June 2009

Completion Date:

June 2012

Related Keywords:

  • Graft Versus Host Disease
  • Hematological Malignancies
  • GVHD
  • HSCT
  • BMT
  • APOPTOTIC CELLS
  • Neoplasms
  • Graft vs Host Disease
  • Hematologic Neoplasms

Name

Location